PA
EGRX

Parallel Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Parallel Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17
Closed -$330 – 3506
2023
Q2 		$330 Sell
17
-108
-86% -$2.56K ﹤0.01% 3180
2023
Q1 		$3.55K Buy
125
+74
+145% +$2.2K ﹤0.01% 2549
2022
Q4 		$1.49K Buy
51
+3
+6% +$95 ﹤0.01% 2790
2022
Q3 		$1K Buy
48
+15
+45% +$550 ﹤0.01% 3062
2022
Q2 		$1K Sell
33
-19
-37% -$873 ﹤0.01% 2904
2022
Q1 		$3K Sell
52
-35
-40% -$1.68K ﹤0.01% 2526
2021
Q4 		$4K Buy
87
+44
+102% +$2.28K ﹤0.01% 2531
2021
Q3 		$2K Buy
43
+17
+65% +$836 ﹤0.01% 2763
2021
Q2 		$1K Hold
26
– – ﹤0.01% 2869
2021
Q1 		$1K Sell
26
-21
-45% -$975 ﹤0.01% 2730
2020
Q4 		$2K Hold
47
– – ﹤0.01% 2373
2020
Q3 		$2K Buy
+47
New +$2.06K ﹤0.01% 2367

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Parallel Advisors's EGRX Position: Q3 2023 in Review

Parallel Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 17 shares — an estimated $330 sold.

Parallel Advisors first reported a position in EGRX in Q3 2020 and held it in 12 quarters. The position peaked at $4K in Q4 2021. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

  • Parallel Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Parallel Advisors sold 17 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $330.
  • Parallel Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2020 and held it in 12 quarters.
  • Parallel Advisors's Eagle Pharmaceuticals, Inc. position peaked at $4K in Q4 2021.
  • 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on Parallel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.